4C medical
A medical device company developing a novel minimally invasive solution for the treatment of mitral regurgitation (MR).
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | $175m | Series D | |
| Total Funding | 000k | ||
Related Content
4C Medical Technologies specializes in developing next-generation minimally invasive technologies for treating structural heart diseases, particularly focusing on mitral regurgitation. Their flagship product, AltaValve, is a transcatheter mitral valve replacement (TMVR) system designed to expand the treatable patient population, streamline procedures, and preserve critical cardiac structures. The company operates in the medical device market, serving healthcare providers and patients suffering from heart conditions. Their business model revolves around the research, development, and commercialization of advanced cardiovascular devices. Revenue is generated through the sale of these devices and potentially through partnerships and licensing agreements.
Keywords: Mitral regurgitation, TMVR, AltaValve, structural heart disease, cardiovascular, minimally invasive, medical devices, healthcare, innovation, patient care.